



Health, Seniors and Long-Term Care

Public Health

300 Carlton Street

Winnipeg, Manitoba Canada R3B 3M9

July 7, 2026

RE: Expanded Paediatric RSV Immunoprophylaxis Program

As of April 1, 2026, all infants are eligible to receive one dose of nirsevimab (an RSV monoclonal antibody product) during their first RSV season (October 1 to March 31).

- **Infants born from October 1 to March 31** should receive nirsevimab **in the birthing facility before being discharged**.
 - If an infant's birth was attended by a midwife outside of a birthing facility, nirsevimab can be given at a follow up visit with the midwife.
 - If an infant did not receive a dose of nirsevimab in the birthing facility, health care providers or local public health offices can recommend and offer the dose to parents.
- **Infants born between April 1 and September 30** can receive nirsevimab in the fall. Providers should plan to offer nirsevimab in **October and November** to all infants on their roster who were born between April 1 and September 30.
 - These infants will be due for either a 2-, 4- or 6- month appointment in October or November, so nirsevimab can be offered at the same time as other routine childhood vaccines at whichever appointment occurs in October or November.

In addition, children with certain high-risk conditions entering their second season may also be eligible in consultation with the Manitoba High-Risk RSV Immunoprophylaxis Program.

Nirsevimab (Beyfortus®) will continue to be the RSV monoclonal antibody available for use in Manitoba. A single dose of nirsevimab is expected to provide protection for up to six months.

Please refer to the following resources for more information:

- FAQ for HCPs: <https://www.gov.mb.ca/health/publichealth/diseases/docs/paediatric-rsv-immunoprophylaxis-program-admin-pathways-faq.pdf>
- Nirsevimab QRG: <https://www.gov.mb.ca/health/publichealth/diseases/docs/nirsevimab-grq.pdf>

Details on how providers will be able to access nirsevimab will be communicated in the coming weeks.



Please share information about the expanded Paediatric RSV Immunoprophylaxis Program to new and expecting parents to promote uptake and potentially reduce RSV-related hospitalizations.

- Resources will be updated in the coming weeks and made available on: <https://www.gov.mb.ca/health/publichealth/diseases/rsv.html>.

Please share this information with all colleagues at your facility/clinic.

Sincerely,

“Original Signed by”

“Original Signed by”

Richard Baydack, PhD
Executive Director
Communicable Disease Prevention and Control

Natalie Casclang, MD, CCFP, FRCPC
Medical Officer of Health
Communicable Disease Prevention and Control